Signpost Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Signpost Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$845K	Sell	16,485 -16,580	-50%	-$766K	2.47%	7
2016 Q4	$1.24M	Sell	33,065 -1,300	-4%	-$54.4K	1.52%	9
2016 Q3	$2.33M	Hold	34,365	–	–	1.96%	12
2016 Q2	$1.91M	Hold	34,365	–	–	1%	12
2016 Q1	$2.16M	Buy	+34,365	New	+$2.28M	1.01%	17

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Signpost Capital Advisors's ALNY Position: Q1 2017 in Review

Signpost Capital Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q1 2017, selling an estimated $766K and leaving 16,485 shares worth $845K. The position accounts for 2.47% of the portfolio, ranked #7.

Signpost Capital Advisors first reported a position in ALNY in Q1 2016 and has held it in 5 quarters since. The position peaked at $2.33M in Q3 2016. 198 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

Signpost Capital Advisors held 16,485 shares of Alnylam Pharmaceuticals worth $845K as of Q1 2017.
Signpost Capital Advisors sold 16,580 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $766K.
Alnylam Pharmaceuticals made up 2.47% of Signpost Capital Advisors's portfolio in Q1 2017, its #7 holding.
Signpost Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 5 quarters since.
Signpost Capital Advisors's Alnylam Pharmaceuticals position peaked at $2.33M in Q3 2016.
198 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Signpost Capital Advisors's 13F filing for Q1 2017, filed 1 May 2017.